Lifecore Biomedical’s (LFCR) Outperform Rating Reaffirmed at Barrington Research

Barrington Research restated their outperform rating on shares of Lifecore Biomedical (NASDAQ:LFCR) in a report issued on Tuesday,Benzinga reports. The firm currently has a $5.50 price target on the stock.

Several other brokerages have also commented on LFCR. Zacks Research raised shares of Lifecore Biomedical to a “hold” rating in a report on Thursday, January 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Lifecore Biomedical currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Lifecore Biomedical Stock Down 1.2%

Shares of LFCR opened at $4.00 on Tuesday. The firm has a market cap of $149.92 million, a P/E ratio of -4.08 and a beta of 0.62. Lifecore Biomedical has a 12 month low of $3.87 and a 12 month high of $8.98. The stock’s 50 day moving average is $7.11 and its two-hundred day moving average is $7.34. The company has a current ratio of 2.80, a quick ratio of 1.67 and a debt-to-equity ratio of 113.76.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Monday, March 16th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.The business had revenue of $35.75 million for the quarter, compared to analyst estimates of $35.31 million. Analysts predict that Lifecore Biomedical will post -0.91 earnings per share for the current fiscal year.

Institutional Trading of Lifecore Biomedical

A number of institutional investors have recently made changes to their positions in the company. Grizzlyrock Capital LLC purchased a new position in Lifecore Biomedical in the 2nd quarter valued at $5,964,000. Greenhaven Road Investment Management L.P. raised its position in shares of Lifecore Biomedical by 2.2% in the second quarter. Greenhaven Road Investment Management L.P. now owns 3,694,832 shares of the company’s stock valued at $30,002,000 after buying an additional 78,686 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Lifecore Biomedical by 62.8% in the second quarter. Intech Investment Management LLC now owns 17,263 shares of the company’s stock valued at $140,000 after buying an additional 6,660 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Lifecore Biomedical in the second quarter worth about $88,000. Finally, State of Wyoming purchased a new position in shares of Lifecore Biomedical in the second quarter worth about $69,000. 83.36% of the stock is owned by institutional investors and hedge funds.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.